News and Trends 25 May 2022 Duke Street Bio enters stage with next-generation cancer therapies The UK startup Duke Street Bio has exited stealth mode with funding to develop PARP enzyme inhibitors that treat cancer by blocking the repair of DNA in tumor cells. London-based Duke Street Bio said Tuesday that it has a portfolio of PARP1 and PARP7 enzyme inhibitors and has raised enough cash to fund its pipeline […] May 25, 2022 - 3 minutesmins - By Susannah Rodgers Share WhatsApp Twitter Linkedin Email
Inside Labiotech 25 May 2022 Labiotech goes global The past few months have been very exciting for our team. Following our recent acquisition by Inova, we’ve been working hard on defining the future of Labiotech. From our humble beginnings in France to our expansion into the European market, we’ve always been keen to explore new horizons for the benefit of our readers. Once […] May 25, 2022 - 3 minutesmins - By Joachim Eeckhout Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2022 Vaccines mobilized to control monkeypox outbreak An unusual outbreak of monkeypox is causing concern worldwide in the shadow of the destructive Covid-19 pandemic. Both old and emerging vaccine technology could aid the fight against the outbreak. In the wake of the world-changing Covid-19 pandemic, the World Health Organization (WHO) is voicing alarm over another unusual outbreak, this time of the viral […] May 24, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 23 May 2022 The coming of age of European synthetic biology Within a few years, synthetic biology has evolved from being a new player in the molecular biology and biotech arena to being a front-row contender with multiple industrial advances and large amounts of investor money. There have been a number of definitions of synthetic biology, also known as synbio. Generally, it involves redesigning genetic systems […] May 23, 2022 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 20 May 2022 Zealand Pharma’s drug for rare metabolic disease smashes phase III After a year of slumping stock prices, Zealand Pharma is striking back, as its peptide drug improved blood sugar control in infants with the rare disease congenital hyperinsulinemia in a phase III trial. In late 2020, the Danish firm Zealand Pharma A/S hit a big obstacle when its peptide drug dasiglucagon failed to treat the […] May 20, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2022 Evotec, Sernova in partnership to develop beta cell diabetes therapy Evotec and Sernova are set to join forces to advance a beta cell replacement therapy to treat insulin-dependent diabetes. As part of the deal, Evotec will make a €20M equity investment in Sernova. Germany-based Evotec and Canada’s Sernova have agreed on a partnership to develop and commercialize an implantable diabetes therapy based on beta cell […] May 19, 2022 - 3 minutesmins - By Susannah Rodgers Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2022 F2G enlists Shionogi to bring antifungal treatment to Europe and Asia The UK company F2G Ltd. has announced a strategic collaboration with Japanese pharmaceutical company Shionogi & Co. Ltd. to develop and commercialize olorofim, an antifungal treatment for invasive fungal infections, in Europe and Asia. The deal centers on olorofim, F2G’s oral antifungal therapy for the treatment of invasive aspergillosis, an infection that can be deadly […] May 19, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Inside Labiotech 19 May 2022 Meet the Future Makers of Labiotech Following our recent acquisition by Inova, our team is expanding! We’re very excited to welcome three new hires to join our international team: Jim, former Editor at DairyReporter, is joining us as Editor-in-Chief. As a music composer, photographer, and podcaster, he is looking to bring in loads of creative energy and explore fun ways to […] May 19, 2022 - 8 minutesmins - By Yi-Jen Chang Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2022 US Giant Apollo Bags Billion-Euro Partnership with Sofinnova As biotech investment slows following a record-breaking year, the Paris-based Sofinnova Partners has landed a €1B collaboration deal with the US investment heavyweight Apollo to nurture life sciences companies. Cementing the trend for transatlantic deals between biotech investors, the US asset manager Apollo has entered into a billion-Euro partnership with the European venture capitalist (VC) […] May 17, 2022 - 3 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2022 Valneva’s Covid-19 Vaccine Contract in Dire Straits as EU Approval Lags The stock price of the French Covid-19 vaccine maker Valneva has been knocked down by 20% as the company faces losing a supply contract with the European Commission. Despite receiving a glowing marketing authorization from the UK’s drug regulator in April this year, Valneva is struggling to gain traction with its Covid-19 vaccine in the […] May 16, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Opinion 16 May 2022 CRISPR Can Help The Switch To Sustainable Cosmetics The cosmetics industry is looking for greener ingredients as consumers demand more sustainable products. According to Jon Kratochvil at ERS Genomics, which licenses out patents belonging to the gene editing pioneers Emmanuelle Charpentier and Jennifer Doudna, CRISPR-Cas9 could one day meet the demand for alternatives. The global cosmetics industry is worth more than €480B ($500B), […] May 16, 2022 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 13 May 2022 Domain Therapeutics Bags €39M to Block GPCRs in Cancer Immunotherapy Domain Therapeutics, a biopharmaceutical company in France and Canada developing cancer immunotherapies targeting G protein-coupled receptors (GPCRs), has closed a €39M ($42M) Series A financing round to move its lead candidate to clinical trials. The approval of the first immune checkpoint inhibitor treatments in 2014 proved a gamechanger for cancer immunotherapy as they prevented tumors […] May 13, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email